• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 2, 2024
Discovery & Translation

Science spotlight: Doudna lab’s cell-penetrating CRISPR RNPs, durable epigenome editing and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Jan 7, 2022
Distillery Therapeutics

NRP1 inhibition for bone marrow regeneration

Read More
BioCentury | Feb 26, 2019
Distillery Therapeutics

Musculoskeletal

Read More
BioCentury | Jun 5, 2018
Distillery Therapeutics

Cancer; ophthalmic disease

Read More
BioCentury | Jan 12, 2017
Emerging Company Profile

Looking beyond VEGF

How SemaThera targets vascular pathologies in the retina where anti-VEGF fails
Read More
BioCentury | Jun 30, 2014
Company News

AmorChem, Hopital Maisonneuve-Rosemont deal

Read More
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Ophthalmic disease

Read More
BioCentury | May 31, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

Read More
BioCentury | Apr 23, 2012
Strategy

Cracking the code

Chiome taps consultants, adapts antibody platform to find deals outside Japan
Read More
BioCentury | Nov 21, 2011
Finance

Chiome IPO in Japan

Japanese antibody play Chiome announces IPO plans; deal with Five Prime
Read More
Items per page:
1 - 10 of 12
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa